$goss

$GOSS sees a surge in social engagement driven by anticipation for its Phase [--] readout, despite underlying concerns about potential failure risks reflected in options markets.

About $goss

$GOSS refers to a decentralized digital currency and its associated blockchain technology.

Engagements: [------] (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [-----]
[--] Week: [------] +5,186,200%
[--] Month: [-------] -44%
[--] Months: [---------] +125%
[--] Year: [---------] +197%
1-Year High: [-------] on 2025-12-24
1-Year Low: [--] on 2025-05-10

Engagements by network (24h): X: [------] Reddit: [--]

Mentions: [--] (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Month: [--] -96%
1-Year High: [-----] on 2025-07-10
1-Year Low: [--] on 2025-04-27

Mentions by network (24h): X: [--] Reddit: [--]

Creators: [--] (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $goss in the last [--] hours which is down 14% from [--] in the previous [--] hours Daily Average: [--]
[--] Month: [--] -94%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-04-27

The most influential creators that mention $goss in the last [--] hours

Creator	Rank	Followers	Posts	Engagements
@BiopharmIQ	[--]	[------]	[--]	[-----]
@BOSSTRADING0	[--]	[-----]	[--]	[---]
@Biopharma_Watch	[--]	[-----]	[--]	[---]
@semodough	[--]	[------]	[--]	[---]
@QuantEmperor	[--]	[-----]	[--]	[---]

Sentiment: 100%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: 100%
Daily Average: 85%
[--] Month: 96% +34%
[--] Months: 96% -4%
[--] Year: 96% +21%
1-Year High: 100% on 2025-02-18
1-Year Low: 14% on 2025-11-11

Most Supportive Themes:

Positive Phase [--] Readout Anticipation: (40%) Multiple posts express optimism about an upcoming Phase [--] readout for $GOSS, with analysts from Barclays, HC Wainwright, and Piper Sandler providing supportive price targets.
Potential for Disease Modification and Market Share: (30%) Discussions highlight $GOSS's potential as a second disease-modifying drug, with analysis on how it could capture market share by catering to specific patient groups or offering convenience.
Biotech Catalyst Watchlist Inclusion: (20%) $GOSS is listed among key biotech stocks with upcoming Phase [--] and Phase [--] readouts in Q1 2026, indicating significant industry attention.

Most Critical Themes:

Options Market Pricing in Failure Risk: (10%) Options data suggests a 70% probability of failure for the Phase [--] readout, with concerns about patient enrollment and statistical significance in previous phases.

Top $goss Social Posts

Top posts by engagements in the last [--] hours

Showing a maximum of [--] top social posts without a LunarCrush subscription.

"** HIGHEST IMPLIED VOLATILITY OPTIONS ** $GRAB $GOSS $KPTI $TBPH $NFE $AMAT $NUAI $FRMI $IMUX $LU $AXTI"
X Link @QuantEmperor 2026-02-17T20:45Z [----] followers, [---] engagements

"Biotech Catalyst Watchlist - Q1 [----] (Stocks Under $5) Probability of approval score card is below $GOSS Phase [--] $TELO Pre-clinical $RCKT PDUFA $MGX Pre-clinical $SXTP Phase [--] $NAYA Phase 1/2a $ATAI Phase [--] $XLO Pre-clinical $ATAI Phase [--] $PYPD NDA $ACRS Phase 1a $NMRA Phase [--] $IMAB Phase 1b $OCGN Phase 2/3 $ANNX Phase [--] $BTAI NDA $BFRI Phase 2b $MBRX Phase 1b/2 $PALI Phase 1b $PMVP Phase [--] $MENS Phase [--] $INMB Phase [--] $GTBP Phase [--] https://www.biopharmawatch.com/company/REGN https://www.biopharmawatch.com/company/REGN"
X Link @Biopharma_Watch 2026-02-17T18:10Z [----] followers, [----] engagements

"$GOSS no pre-announcement. Either meh data or we see results the last week of Feb"
X Link @avidresearch 2026-02-17T02:02Z 12K followers, [----] engagements

"Do we have any examples of a 50/50 rev split biotech hitting on pivitol Asking more out of curiosity. Going to make a note that the market likes to run up clinical biotechs with 50/50 revenue share economics into data readout. $ALEC $GOSS Going to make a note that the market likes to run up clinical biotechs with 50/50 revenue share economics into data readout. $ALEC $GOSS"
X Link @Joshthe3rd_ 2026-02-16T16:54Z [---] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing